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Highlights 
• Frailty is a treatable and potentially reversible syndrome. 
• Frailty increases the risk of disability and/or other adverse health outcomes. 
• Frailty identification is critical in older patients with acute heart failure. 
• Best tool to determine frailty remains to be established. 
• Comprehensive Geriatric Assessment is gold standard instrument for diagnosis of frailty. 
 
 
Abstract 
Acute heart failure (AHF) is a multi-organ dysfunction syndrome. In addition to known cardiac 
dysfunction, non-cardiac comorbidity, frailty and disability are independent risk factors of mortality, 
morbidity, cognitive and functional decline, and risk of institutionalization. Frailty, a treatable and 
potential reversible syndrome very common in older patients with AHF, increases the risk of disability 
and other adverse health outcomes. This position paper highlights the need to identify frailty in order 
to improve prognosis, the risk-benefits of invasive diagnostic and therapeutic procedures, and the 
definition of older-person-centred and integrated care plans. 
 
 
  
1.-INTRODUCTION 
The proportion of people over the age of 65 years is dramatically rising worldwide. It has been 
estimated that more than 30% of Europeans will be over this age in 2050. One consequence of longer 
life expectancy is the increased use of health care services. Although greater age does not necessarily 
imply poorer health, the heterogeneity of the intrinsic capacity varies enormously as a function of age 
between individuals. Ultimately, the different levels of health in aging are better contemplated in 
terms of frailty, rather than years alive that are arbitrary and predominately centred on socio-
demographic aspects1.    
Heart failure (HF) is a chronic disease. It has an incidence and prevalence that are highly age-
dependent. Three out of 4 patients over the age of 75 years suffer with HF2. Acute HF (AHF) is multi-
organ dysfunction syndrome that involves cardiac, renal, pulmonary, cerebral, and hepatic injury. It is 
one of the most frequent causes of visits to emergency departments (ED) and hospitalization3,4. Older 
patients with AHF require a more complex evaluation and have a worse short-term prognosis across 
the spectrum of morbidity, cognitive and functional decline, and the risk of institutionalization and 
mortality, compared to younger adults5,6. Poorer outcomes in older individuals are probably more 
related to comorbidities, frailty and disability than with chronologic age5. 
The terms comorbidity, frailty and disability are associated with aging, and although 
commonly used interchangeably, they are unique entities with different prognoses and health care 
implications7,8  (Figure 1). 
Comorbidity describes a framework where one specific disease is the primary focus, and the 
other distinct entities are comorbid conditions modifying the course and the treatment of an 
individual with the index disease9. In HF patients, the prevalence of comorbidity has increased in the 
last 2 decades10 and is associated with adverse events11.  
Disability is defined as difficulty or dependency in performing activities of daily living7. 
Functional disability is prevalent in HF10, and the level of functional dependence determines a poor 
prognosis in older patients with AHF12. 
Frailty is clinically characterized by a reduction in physiological capacity not necessarily related 
to a specific disease process and typically involves alterations in multiple systems13. Frailty may be 
reversible or attenuated by interventions13. It is more frequent in patients with comorbidity and 
chronic diseases10, particularly HF, than in the general population14. It is associated with higher risks of 
hospitalization, disability and mortality15. Approximately 50-70% of older patients admitted for AHF 
present with some degree of frailty16-18. This contributes to adverse short and long-term outcomes 
both in those managed medically and in relation to interventional procedures18-19.  
Therefore, evaluation of older patients with AHF requires more than assessment of pump 
failure alone20-24. The identification of frailty and its degree is critical to improve prognosis, optimize 
the risk-benefit relationship of invasive diagnostic and therapeutic procedures. An evaluation of fraility 
is also necessary to accurately define older-person-centred and integrated care plans whose main goal 
is to maintain or reverse the potential decline in physical and cognitive capacities (add life to your 
years and not years to your life). 
This position paper highlights the need to recognize that frailty, as a syndrome, is different 
from aging, comorbidity and disability. We will review the definition and diagnosis of frailty and will 
present a practical evaluation and management of it and other possible concurrent circumstances in 
older patients attended with AHF. 
 
  
2.-DEFINITIONS OF FRAILTY 
2.1.-Concept. 
Frailty is a dynamic and nonlinear process. It describes a state of vulnerability to stressors in 
terms of systems reserves and capacity of response to stress situations (i.e., decompensation of AHF) 
in older populations13. This concept may help to identify patients at increased risk of disability and/or 
other adverse health outcomes (i.e. death, reduced physical performance, functional decline, 
hospitalization or institutionalization)13,25. 
 
2.2.-Models of frailty. 
Two main models have been used to conceptualize frailty. These are based on different 
theoretical constructs: 1) a biologic syndrome model and 2) an accumulation of deficiencies model26.  
a.-Frailty phenotype: This model, based on data from the Cardiovascular Health Study, 
considers frailty as a biologic syndrome characterized by the presence of 3 or more of 5 components: 
1) exhaustion, 2) unintentional weight loss, 3) impaired grip strength, 4) slowness, and 5) low physical 
activity27 (Table 1). Subsequently, some authors have proposed variations of the original model by 
introducing new criteria (i.e. cognitive impairment) or even reducing the number of components 
required (i.e. slow gait speed, low physical activity and weight loss)25,28. 
b.-Frailty index (FI): This model, derived from the Canadian Study of Health and Aging, is 
based on deficit accumulation; that is, a measure of the cumulative burden of non-specified age-
associated health deficits (i.e. diseases, impairments in cognition, mood, mobility, or function) 
associated with poor outcomes. The frailty index was originally comprised of 70 measures and 
conceptualized frailty as a continuum. This model counts disabilities and comorbidities and is able to 
quantitatively summarize vulnerability29. 
Numerous other frailty definitions have been developed, but have largely been based on these 
two basic conceptual approaches30. 
 
 
  
3.-TOOLS FOR IDENTIFYING FRAILTY IN OLDER PATIENTS WITH AHF 
3.1.-Screening of frailty in the emergency setting. 
Several screening tools for frailty, based on a multi-domain approach, have been proposed31. 
The tools most frequently studied are the Identification of Seniors at Risk (ISAR)32 and Triage Risk 
Screening Tool (TRST)33.  Both are validated for older patients attending in the Emergency Department 
(ED). These are self-reported (or obtained by a nurse) questionnaires, take approximately 1 minute to 
administer, and are composed of six items related to different domains.  The score ranges from 0 to 6 
(0 = low risk, 6 = high risk). A score of two or more is associated with a greater probability of 
presenting short- and long-term adverse outcomes (hospital readmission, ED revisit, and functional 
decline and mortality) 32,33. These tools have a high sensitivity and relatively low specificity, although 
the predictive capacity for adverse outcomes of the ISAR seems better than that of the TRST31. 
Regarding the frailty syndrome, the ISAR has shown a good predictive capacity in identifying frail older 
patients in the ED34. 
The ISAR is considered a useful screening tool for frailty in older patients presenting to the 
ED34 (Table S1 in supplementary material). Taking into account its limitations35, the use of the ISAR 
alone is inadequate and the cut-off of ≥2 may be useful to select older patients most likely to benefit 
from geriatric assessment34. Some authors have suggested a higher cut-off point, or that consideration 
as a continuous variable, may facilitate more efficient use of care resources31. They suggest a cut-off of 
3 as better in terms of discriminative capacity for adverse outcomes36. 
 
3.2.-Diagnosis of frailty in inpatient units. 
Many of tools have been developed to diagnose frailty in the older population with substantial 
differences in respect to their ability to predict adverse outcomes37. Nonetheless, the reliability and 
validity of these tools have rarely been evaluated38. The few studies in which they were tested were 
epidemiological and their application in the cardiovascular setting, and specifically in HF, is limited39 
(Table 2). Indeed, the best tool to determine frailty for use in research and clinical practice remains to 
be established38. Therefore, when selecting a frailty assessment tool, one must consider where it was 
validated (setting and population), the mode of administration in relation to time-consumption and 
personnel, and the specialized equipment required38. 
Most studies in HF are based on tools derived from the frailty phenotype (Fried Scale) or from 
some of its domains (Physical Performance test)40. There is less evidence on accumulations of deficits 
instruments (i.e. Frailty Index-Comprehensive Geriatric Assessment (FI-CGA) or Tilburg Frailty Indicator 
(TFI)) in the cardiovascular setting39,41 (Table 2). 
The Fried Scale requires 3 or more criteria (exhaustion, unintentional weight loss, impaired 
strength, slowness, and low physical activity) for the diagnosis of physical frailty (Table 1)27. It is 
important to take into account that any modification from the original scale proposed by Fried et al 
2001 may influence the results. In order to compare the different studies available using the frailty 
phenotype, minimum requirements of the measurements must be reported42. 
Several Physical Performance tests have been described, including the Short Physical 
Performance Battery, gait or walking speed, timed-up-and-go test, handgrip strength, and 4 or 6-
minute walk test, each of which may identify physical frailty or preclinical disability in the older 
population43. 
The Short Physical Performance Battery (SPPB) encompasses slowness, weakness, and 
balance. This test assesses lower extremity function using three physical performance tests that 
include standing balance (the ability to stand with the feet together in the side-by-side, semi-tandem, 
and tandem positions), gait speed (time to walk 8 feet or 2.4 metres), and strength and endurance 
(time to rise from a chair and return to the seated position 5 times). The total score ranges from 0-12, 
with higher scores indicating better performance44. The SPPB predicts incident activities of daily living 
disability, worsening mobility and death in older community HF subjects45 (Figure 2).  
Gait speed is a part of the SPPB, but as a single parameter it has been associated with survival 
in older adults46. It is an important risk factor for 1-year mortality in older community population with 
HF47.  The 5-m distance is a good balance between the walking speed achieved and cardiopulmonary 
limitations39.  
Alternatively, the timed get-up-and-go test measures the time needed to complete a series of 
functionally important tasks such as standing up from a chair, walking a short distance, turning 
around, returning to the chair, and sitting down again48. This test appears to be a reliable and valid 
functional measurement in patients with HF49. A gait speed <0.8m/s and a timed-up-and-go test >10s 
are markers of possible frailty in community-dwelling older patients50. In patients with lower limb 
conditions, the handgrip test may be an alternative option51.  
The SPPB is easily applied, preferable to other performance tests (i.e. 4-m walk test, 6-minute 
walk test, and handgrip strength) in community-dwelling older patients with HF45, and it is currently 
considered the best instrument to characterize frailty in clinical trials52. In older patients with HF, a 
total SPPB score ≤4 applied at hospital admission is an independent predictor of the length of hospital 
stay53. Further, its measurement at hospital discharge is an independent predictor of 30-day 
mortality54 and rehospitalisation55. 
Comprehensive Geriatric Assessment (CGA) is the instrument recommended for the 
evaluation and care of frail older patients in clinical practice56. This holistic evaluation is performed by 
a multidisciplinary team that usually includes a geriatrician or other physician knowledgeable in the 
care of older adults, nurse, social worker, pharmacist, and an occupational or physical therapist. This 
team assesses comorbidity, polypharmacy, and cognitive, functional, nutritional, and socio-economic 
areas in order to develop treatment planning and follow-up. The main limitations of the GCA include 
the need to have experts of diverse disciplines and enough time for the evaluation. The CGA has 
demonstrated ability to predict in-hospital and long-term adverse outcomes in older patients 
admitted with HF57-60. Major geriatric syndromes (frailty, severe disability, cognitive, depression) are 
associated with poor intra-hospital and 1-year results in older patients with acute cardiac conditions58. 
The CGA is currently the gold standard to detect frailty and should be used when making complex 
decisions regarding invasive procedures. Because of the limitations mentioned above, some authors 
have proposed a Brief Geriatric Assessment adapted to non-geriatricians using a combination of 
screening scales that approach different domains of the patient61 (Table 3).  
Various instruments derived from CGA have been published (i.e. Multidimensional Prognostic 
Index [MPI], CGA score, and Edmonton Frail Scale [EFS]) that have a high predictive value of adverse 
short-term results. The MPI predicts the 1-month mortality in patients aged 65 years and older 
admitted with AHF57. The CGA score estimates the in-hospital and 2-year mortality in older patients 
hospitalized for AHF59,60. The EFS tool may be useful to identify frailty when considering a surgical 
intervention in order to help with pre-operative optimisation50. 
With regard to the last-mentioned instrument derived from CGA, EFS is a brief 
multidimensional tool that may be applied in older admitted patients by non-geriatricians. It includes 
the domains of cognition, mood, mobility, functional independence, drugs, social support, nutrition, 
health attitudes, continence, medical disease load and quality of life62. The examination takes less 
than 5 minutes and the maximum score (total 17) represents the highest level of frailty62. The new 
version of this scale, the Reported Edmonton Frail Scale (REFS), adapted from the EFS, substitutes the 
get up and go test with self-reporting of physical function before the current illness. The REFS is scored 
from 1 to 1863. With respect to the need for major cardiac interventional or surgical decisions in 
invasive cardiovascular procedures, recent findings have shown that poor agreement among clinicians 
when using the REFS to diagnose frailty, and therefore a geriatric assessment is recommended in 
these cases64. 
 
  
4.-EVALUATION OF FRAILTY IN OLDER PATIENTS WITH AHF 
In all older patients presenting with AHF, the level of frailty must be determined through 
assessment and monitoring of physical and cognitive status during acute management, during 
convalescence and, above all, at the time of hospital discharge50. Some circumstances, such as the 
clinical presentation (i.e. delirium, falls or acute functional decline) or the presence of some level of 
baseline functional dependence in the basic activities of daily living, may be used to indicate possible 
frailty50. Biomarkers are only able to capture single aspects of frailty and are weakly associated with 
clinically meaningful outcomes65. In the absence of universal recommendation as to how to detect 
vulnerable older patients in clinical practice, we suggest a simplistic approach in the ED and ward 
settings (Figure 3). 
 
4.1.- Emergency setting. 
In the ED, where personnel and time resources are limited, we recommend to screen for 
frailty, particularly in patients with non-apparent disability discharged directly from the ED.  We 
recommend using ISAR as a continuous variable, with a cut point ≥2 for maximum sensitivity and ≥3 
for maximum discrimination, to provide an individualized care plan that includes a CGA program. 
 
4.2.-Inpatient units. 
On inpatient units, we recommend that information about comorbidity (Charlson Comorbidity 
Index) (Table S2 in supplementary material)66 and baseline functional status (Barthel Index) (Table S3 
in supplementary material)67, be collected at admission to establish the grade of disability. 
In older patients with established disability (moderate and severe disability), measurement of 
physical frailty should be focused on basic activities of daily living and mobility. The Barthel index has 
shown a greater sensitivity to change and may detect the onset of disability earlier than other scores8 
(Table). Previous studies have shown that severe baseline functional dependence (Barthel index <60 
points) in older patients attended with AHF is associated with an increase in 30-day mortality12, and its 
inclusion in the HF risk stratification models (Bi-EFFECT) has improved the prediction of 30-day 
mortality68. In this profile patient’s information about other domains (e.g., comorbidity, medications, 
cognitive, nutritional and social support) should be included since these variables influence short- and 
long-term prognosis, and care planning decisions58-60. 
We recommend using instruments based on the frailty phenotype (i.e. the Fried scale) or 
physical performance (i.e. SPPB) to diagnose physical frailty in older patients with non-established 
disability (pre-disabled or mild disability)69. The presence of frailty is associated with in-hospital, as 
well as short and long-term outcomes53-55. As mentioned above, there is no single feasible, valid tool 
to diagnose frailty in AHF inpatients and neither has the best time to perform these tests been 
established. Multi-domain tools do not necessarily provide incremental value above single-domain 
tools, and the ease of implementation may be an important factor for adoption. Taking into account 
the acute phase of the heart failure condition, self-reported instruments may be more appropiate at 
hospital admission, while objective performance measures would be better suited at hospital 
discharge.  Finally, some authors have also suggested the addition of cognitive and nutritional status 
to improve the diagnosis of frailty13. 
It is also important to monitor the cognitive and functional situation during hospitalization 
since delirium and acute functional decline are markers of frailty50. Delirium is the main manifestation 
of cognitive frailty and frequently appears in hospitalised elderly patients with cognitive impairment. 
Its presence in patients with decompensated HF has been associated with 30-day mortality70. The 
Confusion Assessment Method (CAM) is a good tool for the identification of delirium71. The CAM for 
the Intensive Care Unit (CAM-ICU)72 has shown to have a better capacity to diagnose delirium in older 
patients in the ED73. It is recommended that cognitive status is evaluated, after ruling-out delirium, at 
the time of the first visit, or failing that, on ward admission. Montreal Cognitive Assessment (MoCA) is 
the best method to screen for cognitive impairment in patients with HF74,75 in both clinical practice 
and trials52. 
 
  
5.-FRAILTY-BASED MANAGEMENT IN OLDER PATIENTS WITH AHF. 
 The management of older patients with AHF should be based on clinical guidelines taking into 
account that older patients, and particularly frail older patients, have often been excluded from 
clinical trials76,77. We recommend measurement of the degree of frailty as well as the documentation 
of the presence or absence of concurrent comorbidity and disability (Figure 4). 
The identification of frailty involves early treatment of the frailty syndrome and close 
monitoring of patient capacities during and after hospitalization in order to minimize disability. The 
most commonly used interventions to treat frailty include, comorbidity optimization, exercise, 
protein-calorie supplementation, and the development of an individualised care and support plan 
based on a CGA50,59. Regarding vitamin D3, it was not demonstrated to improve physical performance 
in spite of the increase in serum 25OHD in older patients with HF78. These interventions can reverse 
frailty, but may have no effect on adverse outcomes (hospitalizations, falls, or performance of 
activities of daily living) in community-living older persons79. The presence of significant functional 
decline or delirium in non-disabled older patients with AHF should be considered as a high-risk 
situation that needs CGA. Frailty should be determined with the currently used risk models for 
decision making. Regarding invasive procedures, the identification of frailty, using frailty criteria80-84 
and performance tests (i.e. 5m-gait speed85,86 and the timed-get up-and-go test87) has helped to 
predict short- and long-term adverse events in patients undergoing transcatheter aortic valve 
replacement80,82, cardiac surgery83, cardiac resynchronization therapy84 and post percutaneus 
coronary interventions81. 
The presence of comorbidities and renal failure may make clinical (i.e. chronic obstructive 
pulmonary disease (COPD)88 and biochemical (i.e. renal failure)89 diagnosis of AHF even more difficult 
in frail older patients. Some comorbidities such as anaemia, renal failure and hyperglycaemia, may 
influence the short and long-term prognosis90-93. The treatment of concurrent conditions in the frail 
older patients with AHF should be optimized by balancing the risk-benefit relation (prioritizations, 
interactions or contraindications) and making adjustments according to creatinine clearance (MDRD-
4). Polypharmacy should be minimized because of the increased risk of adverse events and the 
consequence of potentially reduced adherence. The application of evidence-based medication review 
checklists (e.g. STOPP/START criteria) can be helpful to reduce inappropriate medicine use50. 
Regarding heath care, multi-provider or multi-settings should be avoided, or failing this, they should 
be well coordinated, with close monitoring of active morbidities during both hospitalization and after 
discharge. 
Disabled patients represent the highest risk scenario and require more complex decision-
making regarding treatment and care planning. One out of three patients aged 85 years and older 
(one of six if ≥75 years) attending with AHF in the ED has a moderate or severe disability5. To facilitate 
the determination of frailty, we suggest to distinguishing between patients with middle or moderate 
and severe disability. In moderate disability there may be a thin line dividing consideration for 
therapeutic invasive procedures and their indications (Bathel index 90-40 points). These decisions 
should be based on CGA integrating risk scores, and frailty and disability components. 
Palliative care, ethical constructs, advanced directives, and the rationalisation of medications 
should be considered in patients with non-acute severe disability. There is no evidence to guide end-
of-life decisions for older patients with HF. The usual medications such as beta-blockers, diuretics, 
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, nitroglycerin and digoxin are 
recommended to maintain symptom relief and improve quality of life94. Other treatments such as 
lipid-lowering medications and antiplatelet agents, with the exception of aspirin, may never be 
indicated and anticoagulants and antiarrhythmics may rarely be appropriate95.  
Regarding the transition of care, the discharge of all frail older patients with AHF should 
include a comprehensive care and support plan. This should involve plans for optimisation and 
maintenance, self-care, escalation (what to look for and who to call), and emergency responses that 
may include whether or not hospital care is appropriate/desirable and what alternatives are in place50. 
All these aspects are important in order to improve subjective and objective quality of life in older 
patients with AHF96. 
 
  
6.-CONCLUSIONS. 
In conclusions, 1) AHF is a multi-organ dysfunction syndrome. In addition to cardiac, renal, 
pulmonary, cerebral, and hepatic injuries, as well as non-cardiac comorbidity, frailty and disability are 
independent factors predicting mortality, morbidity, cognitive and functional decline, and the risk of 
institutionalization in older patients with AHF; 2) Frailty (or state of vulnerability to stressors) is a 
treatable and potentially reversible syndrome which increases the risk of disability and/or other 
adverse health outcomes; 3) Frailty identification is critical in older patients with AHF in order to 
improve the stratification of prognosis (disposition), the evaluation of the risk-benefits of invasive 
diagnostic and therapeutic procedures and the development of older-person-centred and integrated 
care plans (person-centred coordinated care) which have the main goal of maintaining or reversing 
potential declines in physical and cognitive capacities; 4) Though the best tool to determine frailty for 
use in research and clinical practice remains to be established, we recommend the ISAR for the 
screening of frailty in ED, and the Fried phenotype (i.e. Fried Scale) and Physical Performance Test (i.e. 
SPPB) for the diagnosis of frailty during the hospitalization of older patients with AHF; 5) CGA (or 
instruments derived from CGA) is the instrument recommended for the evaluation and care of frail 
older patients in clinical practice. 
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TABLES AND FIGURES. 
Table 1.-Fried Criteria. 
 
 Original frailty phenotype 
(as proposed by Fried et al. 2001) Self-Reported Deficit 
Exhaustion 
 
How often in the last week did you feel this way? (a) I felt that 
everything I did was an effort; (b) I could not get going 
 
A moderate amount of the time (3–4 days) or most of the time = 1;  
rarely or none of the time (<1 day) or some or a little of the time (1–2 
days) = 0  
 
 
Self-report of fatigue or felt unusually 
tired or weak in the past month. 
Weight loss 
 
In the last year, have you lost more than 5kg unintentionally (i.e., not 
due to dieting or exercise)? yes=1, no=0 
 
Self-report weight loss > 5kg 
unintentionally in the past year. 
Physical activity 
 
Minnesota Leisure Time Activity Questionnaire (past 2 weeks): 
walking, chores (moderately strenuous), mowing the lawn, raking, 
gardening, hiking, jogging, biking, exercise cycling, dancing, aerobics, 
bowling, golf, singles tennis, doubles tennis, racquetball, calisthenics, 
swimming. Deficit given to (adjusted by sex)  
-Men: Kcals/week < 383;  
-Women: Kcals/week < 270 
 
Self-report frequency and duration of 
physical activities. 
 
Grip strength 
 
Average grip strength score in dominant hand (3 trials) using JAMAR 
hand held dynamometer Deficit given to (adjusted by sex and BMI 
quartile based on CHS population by Fried et al. 2001) 
 
-Men: BMI ≤24kg and strength <29kg; BMI 24.1–26 and strength <30; 
Men: BMI 26.1-28kg and strength <30kg; BMI24.1–26_and strength 
<30; BMI >28 and strength <32 kg 
-Women: BMI ≤23kg and strength <17kg; BMI 23.1–26 and strength 
<17.3; Men: BMI 26.1-29kg and strength <18kg; BMI >29 and strength 
<21kg 
 
Self-report of difficulty standing up from a 
chair. 
 
Walking time 
 
Walking speed score (15 ft (5m) test, usual pace, one trial) 
Deficit given to (adjusted by sex and median height based on CHS 
population by Fried et al. 2001) 
 
-Men: height ≤173cm and speed ≤0.6531 m/s; height>173cm and 
speed ≤0.762 m/s 
-Women:height ≤159cm and speed ≤0.6531m/s; height >159cm and 
speed ≤0.762 m/s 
 
Self-report of any difficulty for walking 
100m. 
 
5 items: 0 deficits: nonfrail; 1-2 deficits: prefrail; ≥3 deficits: frail. 
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 Table 2.-Principal studies about frailty in older patients with acute heart failure. 
 
 
Setting 
 
Items 
 
Score (cut-off) 
 
Administer 
 
Domains 
 
Subjects 
 
Outcomes 
 
Emergency Department 
 
ISAR 
Identification Seniors at Risk 
Mc.Clusker 1999 
 
6 0 - 6 
(≥ 2 = frailty) 
Self-reported  
 
Cognition, ADL, Medications, Vision, Recent 
hospitalization 
Patients ≥ 65 years 
discharged from ED 
30-day mortality  
30-day hospital readmission 
30-day functional decline 
 
 
Inpatients Unit  
 
SPPB 
Short Physical Performance 
Battery 
Volpato 2008 2011 
Chiarantini 2010 
 
3 0-12 (< 5 = frailty) Physical performance 
5-m gait speed test  
Chair rise test  
Balance test 
Patients ≥ 65 years        
admitted for AHF 
Length of stay 
Incident disability 
15-month mortality 
 
TFI 
Tilburg Frailty Indicator 
Uchmanowicz I 2015 
 
 
15 
0-15 
(≥5 = frailty) Self-reported 
 
Physical (8), Psychological (4), Social (3). 
 
Patients ≥ 60 years        
admitted for AHF 
Self-care capabilities 
Health-related quality of life 
 
MPI 
Multi prognostic index 
Pilotto 2010 
 
63 
 
 
0-1  
(0.34–0.66 = 
moderate risk;  
0.67-1 = high risk) 
 
Data abstracted out of 
CGA by geriatrician 
Cognition, ADL, Nutrition, Comorbidities, 
Medications, Decubitus, Social support 
Patients ≥ 65 years        
admitted for AHF 1-month mortality 
 
CGA Score 
Rodriguez Pascual 2012 2014 
 
5 
0-10 
(≤2: lower risk; 3-
4; 5-6; ≥7: higher 
risk) 
Data abstracted out of 
CGA by geriatrician 
 
Cognition, ADL, Mobility, Comorbidity, 
Medicactions 
 
Patients ≥ 75 years        
admitted for AHF 
In-hospital mortality 
2-year mortality 
IADL: instrumental activities of daily living 
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Table 3.-Brief Geriatric Assessment based on Comprehensive Geriatric Assessment. 
 
Domain Tool 
Cognitive 
 
Montreal Cognitive Assessment (MOCA) 
 
 
Depression 5-item Geriatric Depression Scale (5-GDS) 
Functional 
 
Lawton index (LI) (8 instrumental activities of daily living) 
Barthel index (BI) (8 basic activities of daily living and 2 of mobility). 
 
Nutrition 
 
Mini-Nutritional Status – Short Form (MNA-SF) 
Serum albumin 
 
Polypharmacy 
 
START and STOPP Criteria 
 
Comorbidity 
 
Charlson Comobidity Index 
 
Hearing   
 
Whispering test 
 
Visual 
 
Snellen test 
 
Socio-economic 
 
Gijon’s social-familial evaluation scale (SFES) 
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SUPPLEMENTARY MATERIAL. 
 
Table S1.-Identification of Senior At Risk Tool. 
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Table S2.-Charlson Cormobidity Index. 
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Table S3.-Barthel Index.  
 
 
 
 
 
Frail Older patients attended for AHF 1 
Figure 1.-Practical approach to assess the vulnerability in older patients with acute heart failure. 
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Figure 2.-Short Physical Performance Battery. 
 
*See the videos in the supplementary electronic material. 
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Figure 3.-Approach to assess the frailty in older patients with acute heart failure. 
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Figure 4.-Management of older patients with acute heart failure based on frailty. 
 
  
 
  
